Abstract
The pathogenesis of obesity, insulin resistance and hypertension begins with an interaction between genetic factors and environmental factors. The search for the underlying genetic basis of these conditions has yielded disappointing results. It is possible that the importance of environmental influences has been underestimated. In Part Two of our series of reviews, we discuss the key genetic, environmental and evolutionary influences which lead to the development of these conditions, and provide a detailed account of the mechanisms by which these influences produce their effects.
Keywords: Metabolic syndrome, hypertension, obesity, insulin resistance, epidemiology, gene-environment interaction, reninangiotensin system, candidate gene approach, genome wide scanning, intermediate phenotype
Current Vascular Pharmacology
Title: The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Volume: 4 Issue: 4
Keywords: Metabolic syndrome, hypertension, obesity, insulin resistance, epidemiology, gene-environment interaction, reninangiotensin system, candidate gene approach, genome wide scanning, intermediate phenotype
Abstract: The pathogenesis of obesity, insulin resistance and hypertension begins with an interaction between genetic factors and environmental factors. The search for the underlying genetic basis of these conditions has yielded disappointing results. It is possible that the importance of environmental influences has been underestimated. In Part Two of our series of reviews, we discuss the key genetic, environmental and evolutionary influences which lead to the development of these conditions, and provide a detailed account of the mechanisms by which these influences produce their effects.
Export Options
About this article
Cite this article as:
The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction, Current Vascular Pharmacology 2006; 4 (4) . https://dx.doi.org/10.2174/157016106778521661
DOI https://dx.doi.org/10.2174/157016106778521661 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews The Potential Role of Thiamine (Vitamin B1) in Diabetic Complications
Current Diabetes Reviews Therapeutic Potential of Coagonists of Glucagon and GLP-1
Cardiovascular & Hematological Agents in Medicinal Chemistry Determinants of Use of Long-term Continuous Electrocardiographic Monitoring for Acute Ischemic Stroke Patients without Atrial Fibrillation at Baseline
Current Neurovascular Research Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) VEGF, a Mediator of the Effect of Experience on Hippocampal Neurogenesis
Current Alzheimer Research Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design Bovine lactoferrin as a Modulator of Neuroendocrine Components of Stress
Current Molecular Pharmacology Role of WNK Kinases in Blood Pressure Control
Current Hypertension Reviews Adrenomedullins: Therapeutic Potential in Cardiovascular Disease
Current Hypertension Reviews Nanomedicine for Intranasal Delivery to Improve Brain Uptake
Current Drug Delivery Preface [Hot Topic: Obesity Drug Design (Executive Editor : Christian Weyer)].
Current Pharmaceutical Design The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis
Current Vascular Pharmacology Tityus serrulatus Scorpion Venom and Toxins: An Overview
Protein & Peptide Letters Human Pluripotent Stem Cells for Modelling Human Liver Diseases and Cell Therapy
Current Gene Therapy The Role of Prostaglandins in Liver Ischemia-Reperfusion Injury
Current Pharmaceutical Design The Key Role of Medullary 5-HT3 Receptors in the Serotonin-Mediated Neural Control of Cardiovascular Function
Current Neuropharmacology